Mycophenolate mofetil causing deep venous thrombosis in a renal transplant patient with factor V Leiden

Nephrology Dialysis Transplantation

Volumn 16, Issue 8, 2001, Pages 1702-1704

  Cherney, David Z I ^a   Zaltzman, Jeffrey S ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Deep venous thrombosis; Factor V Leiden; Mycophenolate mofetil; Renal transplantation

Indexed keywords

AZATHIOPRINE; BLOOD CLOTTING FACTOR 5 LEIDEN; CREATININE; CYCLOSPORIN A; DOXAPRAM; LOW MOLECULAR WEIGHT HEPARIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; WARFARIN;

ADULT; ARTICLE; CASE REPORT; DEEP VEIN THROMBOSIS; DOPPLER ECHOGRAPHY; DRUG WITHDRAWAL; FEMALE; HETEROZYGOSITY; HUMAN; ILIAC VEIN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; LEG EDEMA; MEMBRANOUS GLOMERULONEPHRITIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NOSE DISEASE; PERITONEAL DIALYSIS; POPLITEAL VEIN; PRIORITY JOURNAL;

EID: 0034877861     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/16.8.1702     Document Type: Article

References (15)

1. Mechanisms of action of new immunosuppressive drugs
2. RS-61443 for treatment-resistant human liver rejection
3. Maintenance of immunosuppression with prednisone and RS-61443 alone following liver transplantation
4. Mycophenolate mofetil in renal allograft recipients: A pooled efficacy analysis of three randomized double-blind, clinical studies in prevention of rejection
5. Treatment of recurrent heart rejection with mycophenolate mofetil (RS-61443): Initial clinical experience
6. Newer immunosuppressive drugs: A review
7. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection
8. Mycophenolate mofetil and its mechanisms of action
9. Factor V Leiden mutation and the risks for thromboembolic disease: A clinical perspective 1997
10. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Leiden Thrombophilia Study
11. Mutation in the gene coding for coagulation factor V and the risk for myocardial infarction, stroke, and venous thrombosis in apparently healthy men
12. Venous thromboembolic complications after kidney and kidney-pancreas transplantation: A multivariate analysis
13. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Leiden Thrombophilia Study
14. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic thromboembolism